Bicara Therapeutics
BCAX
93 hedge funds and large institutions have $634M invested in Bicara Therapeutics in 2025 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 18 closing their positions.
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
11% more funds holding
Funds holding: 84 → 93 (+9)
3.49% more ownership
Funds ownership: 85.83% → 89.32% (+3.5%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
22% less capital invested
Capital invested by funds: $814M → $634M (-$180M)
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$27.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.8M |
| 3 |
Morgan Stanley
New York
|
+$9.95M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.46M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$6.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$31.3M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.2M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$6.64M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$6.03M |
BCAX Hedge Fund Activity: Q1 2025 in Review
93 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q1 2025, worth a combined $634M — down 22% from $814M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BCAX positions and 18 closed out — a net gain of 9 holders — while 26 added to existing stakes and 19 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $27.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $31.3M sold.
- 93 institutional investors held Bicara Therapeutics (BCAX) as of Q1 2025, up from 84 in Q4 2024.
- Funds reported $634M of Bicara Therapeutics stock for Q1 2025, down 22% quarter-over-quarter.
- 27 funds opened new Bicara Therapeutics positions in Q1 2025 and 18 closed out, a net change of +9 holders.
- The largest Bicara Therapeutics buyer in Q1 2025 was Vestal Point Capital, an estimated $27.3M added.
- The largest Bicara Therapeutics seller in Q1 2025 was Deerfield Management, an estimated $31.3M sold.
Based on aggregated 13F filings for Q1 2025.